Compounding pharmacies will need to wait to see the outcome of the July 23-24 meeting before being able to employ these bulk drug substances in compounding
Are there any serious safety concerns with GLP-1 therapy
These drugs fall within two categories: human GLP-1 backbone agents (that is, albiglutide, dulaglutide, liraglutide and semaglutide) and exendin-4 backbone agents (that is, exenatide, lixisenatide and tirzepatidethe latter activating both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors) 1
Intended Use: Reconstitution of lyophilized research peptides Laboratory dilutions requiring bacteriostatic conditions Multi-use sterile laboratory applications IGF-1 LR3 IGF-1 LR3 Peptide IGF-1 LR3 Peptide (Long Arg3 Insulin-Like Growth Factor-1) 1mg (Lyophilized Peptide) For Research Use Only IGF-1 LR3 is a synthetic analog of human Insulin-Like Growth Factor-1 (IGF-1), modified to extend its half-life in vitro through substitution of arginine at position 3 and removal of the first three amino acids of the native IGF-1 sequence
Compound: CJC-1295 + Ipamorelin
For a 100mg vial, add 4.0mL BAC water (resulting concentration: 25mg/mL, or adjust to your preferred working concentration)
